GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » EPS without NRI

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) EPS without NRI : $-1.63 (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals EPS without NRI?

Dicerna Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Sep. 2021 was $-0.22. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Dicerna Pharmaceuticals's EPS without NRI or its related term are showing as below:

DRNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -6.9   Med: 19.7   Max: 84.1
Current: 25.4

DRNA's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs DRNA: 25.40

Dicerna Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2021 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.63.

Dicerna Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2021 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.63.


Dicerna Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Dicerna Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals EPS without NRI Chart

Dicerna Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -3.66 -1.60 -1.76 -1.52

Dicerna Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.49 -0.39 -0.53 -0.22

Competitive Comparison of Dicerna Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Dicerna Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dicerna Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dicerna Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Dicerna Pharmaceuticals's PE Ratio without NRI falls into.



Dicerna Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dicerna Pharmaceuticals  (NAS:DRNA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dicerna Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Executives
Bob D Brown officer: See Remarks 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye officer: EVP & Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin director
Douglas Fambrough director, officer: President and CEO C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman officer: Chief Operating Officer & EVP C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia officer: Chief Human Resources Officer C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli officer: Chief Commercial Officer DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray director C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Martin I Freed director 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Headlines

From GuruFocus